Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement
Open Access
- 12 March 2019
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (5) , 807-815
Abstract
Background: As novel systemic therapeutics for patients with atopic dermatitis (AD) are developed, ethical and methodological concerns regarding placebo‐controlled‐trials (PCT) have surfaced.Objective: To guide the design and implementation of PCT in AD, focusing on trials with systemic medications.Methods: A subgroup of the International Eczema Council (IEC) developed a consensus e‐survey, which was disseminated to IEC members.Results: The response rate was 43/82 (52%). Consensus was reached on 24/27 statements and on 3/11 options from multiple‐selection statements, including: performing monotherapy studies in proof‐of‐concept phases; avoiding concomitant topical corticosteroids or calcineurin inhibitors until a predefined timepoint as rescue (borderline consensus); selection of sites and assessors with recognized expertise in AD clinical trials; clear definition and identification of baseline disease severity; minimizing time and proportion of patients on placebo; using daily emollients with several options provided; instigating open‐label extension studies for enrolment after a predefined timepoint; and including outcomes which set a higher bar for disease clearance.Conclusion: Conducting PCT in AD requires balancing several, sometimes opposing principles, including ethics, methodology, regulatory requirements and real‐world needs. This paper can provide a framework for conducting PCT with systemic medications for patients with AD.Keywords
Funding Information
- GlaxoSmithKline
- LEO Pharma Research Foundation
- MedImmune
- Genzyme
- AbbVie
- Amgen
- Celgene
- Chugai Pharmaceutical
- Galderma
- Eli Lilly and Company
- Novartis
- Les Laboratories Pierre Fabre
- Pfizer
- Sanofi
- Valeant Pharmaceuticals International
This publication has 39 references indexed in Scilit:
- Warm, Humid, and High Sun Exposure Climates Are Associated with Poorly Controlled Eczema: PEER (Pediatric Eczema Elective Registry) Cohort, 2004–2012Journal of Investigative Dermatology, 2014
- Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meetingAllergy, 2012
- Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatmentArchives of Dermatological Research, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IJournal of the European Academy of Dermatology and Venereology, 2012
- Relationship between itch and psychological status of patients with atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2012
- The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitisBritish Journal of Dermatology, 2011
- A Randomized Controlled Pilot Study of the Effects of an Extra Office Visit on Adherence and Outcomes in Atopic DermatitisArchives of Dermatology, 2010
- Climate and prevalence of atopic eczema in 6- to 7-year-old school children in Spain. ISAAC PhASE IIIInternational Journal of Biometeorology, 2008
- Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatmentsJournal of the American Academy of Dermatology, 2007
- The Ethics of Placebo-Controlled Trials — A Middle GroundNew England Journal of Medicine, 2001